Immunomedics (IMMU) Misses Q2 EPS by 50c

Immunomedics (NASDAQ: IMMU) reported Q2 EPS of ($0.84), $0.50 worse than the analyst estimate of ($0.34).

As of December 31, 2018, the Company had $497.8 million in cash, cash equivalents, and marketable securities, which it believes is adequate to support its clinical development plan for sacituzumab govitecan; further build its clinical and manufacturing infrastructure and fund its operations through 2020.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order